OMass Therapeutics
Updated: October 15, 2026
Ros Deegan, CEO
Country: UK | Funding: $472.3M (+)
Founded: 2016
Website: https://www.omass.com/
OMass Therapeutics develops new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry. Its lead candidate, a melanocortin-2 (MC2) receptor antagonist dubbed OMS1620 is targeted at congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome.
Founded: 2016
Website: https://www.omass.com/
OMass Therapeutics develops new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry. Its lead candidate, a melanocortin-2 (MC2) receptor antagonist dubbed OMS1620 is targeted at congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome.
